Is Egrifta (Tesamorelin) Legal in Tennessee?
HealthRX.com
Egrifta is FDA-approved, so it is legal with a prescription
Key numbers
- 47%Share of patients treated for 26 weeks whose IGF-1 rose above 2 SDSSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.4 mgOnce-daily dose of Egrifta SV, the 2 mg vial formulation, injected under the skinSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.28 mgOnce-daily dose of Egrifta WR, the 11.6 mg vial formulationSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 5%Share of patients on tesamorelin with HbA1c of 6.5% or higher by week 26 (placebo: 1%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once-daily subcutaneous injections [2][3]
- Compounding / FDA has made no category-based statement about compounding tesamorelin [4][5][6]
- Sport / WADA prohibits tesamorelin at all times, in and out of competition [7][8]
- Not approved for / Weight loss, anti-aging or muscle building [2]
What the FDA approval covers
Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GHRF, also called GHRH): the 44-amino-acid human sequence plus a hexenoyl group on the N-terminal tyrosine [2]. It binds and stimulates GRF receptors on pituitary somatotroph cells, so the pituitary makes and releases more of the body's own growth hormone, which then raises IGF-1 and IGFBP-3 [2]. It is a peptide, not growth hormone and not a steroid [2].
The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label lists these limits: long-term cardiovascular safety has not been established; the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue; and the drug is not indicated for weight loss management, which the label describes as a weight-neutral effect. The label also says there are no data that it improves adherence to antiretroviral therapy [2].
Two formulations are currently marketed. Egrifta SV is a 2 mg vial given as 1.4 mg once daily, and Egrifta WR is an 11.6 mg vial given as 1.28 mg once daily; both labels are dated July 29, 2026, and the labels state that the two are not substitutable [2][3].
Compounding: what the federal position says
FDA keeps two lists of bulk drug substances: one for state-licensed pharmacies and physicians (updated May 14, 2026) and one for outsourcing facilities (updated March 21, 2025). Tesamorelin appears in no category on either list, and it is not on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) [4][5][6]. FDA has therefore made no category-based statement about compounding it [4][5][6]. Tesamorelin is already a component of an FDA-approved product [1].
The HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026 (Federal Register document 2026-22192), names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of them [9][10].
Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before they are marketed [11].
Tennessee
The status described on this page is the federal one: Egrifta is an FDA-approved prescription medicine. The facts here do not address any Tennessee-specific requirements.
Questions worth asking
What the labels list as contraindications and warnings
Contraindications are disruption of the hypothalamic-pituitary axis (for example hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3]. Both labels also warn about:
- Neoplasms: tesamorelin raises GH, a growth factor, and the labels say to discontinue if there is evidence of recurrent malignancy [2].
- Elevated IGF-1: the labels say to monitor IGF-1; among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2].
- Glucose intolerance or diabetes: HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, hazard ratio about 3.3 (95% CI 1.4 to 9.6) [2].
- Fluid retention, hypersensitivity and injection sites: hypersensitivity reactions occurred in 4% of patients in trials, and injection site reactions in 25% on tesamorelin versus 14% on placebo during the first 26 weeks [2].
Athletes
WADA's Prohibited List names tesamorelin under S2.2.4 (growth hormone releasing factors), and it is prohibited at all times, in and out of competition [7]. It is on the 2026 List, in force since January 1, 2026, and remains on the tracked-changes version of the 2027 List dated 26 August 2026 [7][8].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Tennessee?
What is Egrifta approved to treat?
Is compounded tesamorelin FDA-approved?
What dose do the current Egrifta products use?
Can athletes use tesamorelin?
What are the main warnings on the Egrifta labels?
References
Show all 11 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- Human Drug Compounding Laws | FDA.